temsirolimus + dexamethasone sodium phosphate

**Temsirolimus + dexamethasone sodium phosphate** is a combination regimen used experimentally in oncology, notably in the salvage treatment of relapsed or refractory diffuse large B-cell lymphoma. Temsirolimus is an intravenously administered inhibitor of mammalian target of rapamycin (mTOR), which impedes cell-cycle progression and angiogenesis by blocking downstream signaling, resulting in anti-proliferative and antiangiogenic effects[1][2]. Dexamethasone sodium phosphate is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties; it acts by binding the glucocorticoid receptor and modulating gene transcription to suppress immune and inflammatory responses[3]. The combination has been used as part of multi-agent regimens (e.g., with rituximab, cytarabine, and platinum agents) for aggressive lymphoid neoplasms in clinical trials.

Other names

temsirolimus and dexamethasone sodium phosphate